Bellicum Pharmaceuticals, Inc. (BLCM) Stake Increased by Teachers Advisors LLC

Marco Green
June 24, 2017

Valuation Ratios of Bellicum Pharmaceuticals, Inc. In the past three months the stock value plunged -11.97%. The stock dropped -4.83% the day following the earnings was released, and on 7th day price change was 8.37%. Dynamic Technology Lab Private Ltd owned approximately 0.08% of Bellicum Pharmaceuticals at the end of the most recent reporting period.

Several other institutional investors have also bought and sold shares of BLCM. On average, analysts anticipate that Bellicum Pharmaceuticals will post ($2.84) EPS for the current year. American International Group Inc. now owns 12,902 shares of the biopharmaceutical company's stock worth $159,000 after buying an additional 852 shares in the last quarter. Fox Run Management L.L.C. purchased a new position in Bellicum Pharmaceuticals during the first quarter valued at $171,000. Finally, Allianz Asset Management AG bought a new position in Bellicum Pharmaceuticals during the fourth quarter valued at approximately $297,000. The Return on Invested Capital is a ratio that determines whether a company is profitable or not. The Price Range of Oramed Pharmaceuticals Inc. (NASDAQ:BLCM) dropped -1.79% to hit $12.65. The stock is noticeable among investors as BLCM reported favorable performance of 2.64%. The Company kept a record of 28.94 million floated shares and 30.62 million shares outstanding. The Price Range 52 Weeks is one of the tools that investors use to determine the lowest and highest price at which a stock has traded in the previous 52 weeks.

Now we'll take a look at how the fundamentals are stacking up for Bellicum Pharmaceuticals Inc (BLCM). Nonetheless, from here on out, earnings per share forecasts for the current quarter are $-0.66. Bellicum Pharmaceuticals had a negative net margin of 17,957.31% and a negative return on equity of 63.42%. The firm had revenue of $0.13 million during the quarter, compared to analyst estimates of $0.09 million. The business's quarterly revenue was up 39.1% compared to the same quarter previous year.

Bellicum Pharmaceuticals, Inc. (BLCM)'s Bullish picture have been built after taking the consideration of last five trading activity.

TRADEMARK VIOLATION NOTICE: This piece was first published by Stock Observer and is the sole property of of Stock Observer. If you are reading this article on another website, it was stolen and reposted in violation of global trademark and copyright laws.

Bellicum Pharmaceuticals, Inc. (BLCM) has a market capitalization of 394.39 Million while its Major Index membership is at 0.

In order to reach an opinion and communicate the value and volatility of a covered security, analysts research public financial statements, listen in on conference calls and talk to managers and the customers of a company, typically in an attempt to capture the findings for a research report.

06/02/2016 - SunTrust began new coverage on Bellicum Pharmaceuticals, Inc. giving the company a "buy" rating.

Bellicum Pharmaceuticals, Inc. has a 1-year low of $9.71 and a 1-year high of $23.11. The stock of Intersect ENT Inc (NASDAQ:XENT) has "Outperform" rating given on Tuesday, March 29 by Northland Capital.

Cantor Fitzgerald analyst Elemer Piros reiterated a Buy rating on Bellicum Pharmaceuticals (NASDAQ: BLCM) today and set a price target of $32.

In the transaction dated December 15, 2016, the great number of shares disposed came courtesy the Chief Technology Officer; Slawin Kevin M. disposed a total of 30,000 shares at an average price of $15.45, amounting to approximately $463,500. Advisors Lp Baker acquired 166,666 shares of the stock in a transaction on Friday, March 24th. The company recently closed its share at $12.90 and the company has managed to maintain its sales ratio of about 884.58 versus that of the industry average of 113.19. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CFO Alan A. Musso sold 6,311 shares of the stock in a transaction dated Thursday, May 25th.

Other reports by Click Lancashire

Discuss This Article

FOLLOW OUR NEWSPAPER